Revenue and EBITDA grew 25% and 37% YoY, respectively, in Q1 FY27, driven by strong performance in Specialty Chemicals, Nutrition, and Chemical Intermediates. Margins improved across all segments, with continued investments in capacity and R&D supporting future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.